3,440 reports of this reaction
4.2% of all OFATUMUMAB reports
#5 most reported adverse reaction
CHILLS is the #5 most commonly reported adverse reaction for OFATUMUMAB, manufactured by Novartis Pharmaceuticals Corporation. There are 3,440 FDA adverse event reports linking OFATUMUMAB to CHILLS. This represents approximately 4.2% of all 82,579 adverse event reports for this drug.
OFATUMUMAB has an overall safety score of 78 out of 100. Patients taking OFATUMUMAB who experience chills should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CHILLS is moderately reported among OFATUMUMAB users, representing a notable but not dominant share of adverse events.
In addition to chills, the following adverse reactions have been reported for OFATUMUMAB:
The following drugs have also been linked to chills in FDA adverse event reports:
CHILLS has been reported as an adverse event in 3,440 FDA reports for OFATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
CHILLS accounts for approximately 4.2% of all adverse event reports for OFATUMUMAB, making it a notable side effect.
If you experience chills while taking OFATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.